Europe
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
There’s money on the move and venture capital firms launch several biotech companies with hefty Series A financing rounds. Here’s a look.
April showers bring May dollars. Here’s whose cash gardens are really blooming this week in the life sciences world.
Companies across the biotech and biopharma industries recently reported a slew of new leadership appointments, several of which have been explicitly focused on the fields of oncology and precision medicine.
Please check out the biopharma industry’s COVID-19 stories that are trending for May 4, 2021.
There is also a tacit acknowledgment in the industry that the ALSFRS-R (revised) scale needs to evolve.
Two weeks after announcing plans for initial public offerings, Gyroscope Therapeutics and Talaris Therapeutics have now set the terms for their debut on the Nasdaq.
The regulatory nod marks the first time the FDA approved an SGLT2 inhibitor for the treatment of CKD regardless of diabetes status.
BioSpace takes an in-depth look at the Top 25 of Q1. You should be aware of these biopharma companies as they hold a great future ahead. So, check them out.
Although clinical trial news related to COVID-19 was slow last week, there’s quite a bit of news on studies for other indications.
PRESS RELEASES